Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zishen Yufei wan for unexplained recurrent abortion
ChiCTR2200065326Phase 3Not yet recruiting
- Sponsor
- Chongqing Health Center for Women and Children
- Start
- Nov 2022
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Zishen Yufei Wan in recurrent miscarriage (RPL) (2 arms), sponsored by Chongqing Health Center for Women and Children. Primary endpoint: live birth rate. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
Zishen Yufei Wan
03
Conditions
recurrent miscarriage (RPL)
Beyond the preview
Go deeper on ChiCTR2200065326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065326.